SUPN Share Price

Open 34.35 Change Price %
High 36.05 1 Day 1.60 4.69
Low 34.35 1 Week 1.60 4.69
Close 35.75 1 Month 3.15 9.66
Volume 821965 1 Year 16.60 86.68
52 Week High 36.05
52 Week Low 17.25
SUPN Important Levels
Resistance 2 37.33
Resistance 1 36.68
Pivot 35.38
Support 1 34.82
Support 2 34.17
NASDAQ USA Most Active Stocks
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
DCTH 0.02 0.00%
SUSQ 14.20 -0.77%
ASTI 0.00 0.00%
SIRI 5.29 3.32%
More..
NASDAQ USA Top Gainers Stocks
SPIR 0.02 100.00%
LOCM 0.09 50.00%
NIHD 0.74 39.62%
NIHD 0.74 39.62%
WRES 0.09 28.57%
CGEI 0.28 27.27%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
AEZS 1.18 22.92%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
CLSN 0.23 -93.11%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%
More..

Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN)

SUPN Technical Analysis 5
As on 26th May 2017 SUPN Share Price closed @ 35.75 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 25.25 & Strong Buy for SHORT-TERM with Stoploss of 31.58 we also expect STOCK to react on Following IMPORTANT LEVELS.
SUPN Target for May
1st Target up-side 34.83
2nd Target up-side 36.4
3rd Target up-side 37.97
1st Target down-side 30.37
2nd Target down-side 28.8
3rd Target down-side 27.23
SUPN Other Details
Segment EQ
Market Capital 306384160.00
Sector Healthcare
Industry Drugs - Generic
Offical website http://www.supernus.com
SUPN Address
SUPN
1550 East Gude Drive
Rockville, MD 20850
United States
Phone: 301-838-2500
Interactive Technical Analysis Chart Supernus Pharmaceuticals, Inc. ( SUPN NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Supernus Pharmaceuticals, Inc.
SUPN Business Profile
Supernus Pharmaceuticals, Inc. (Supernus) is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Supernus is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit hyperactivity disorder (ADHD). Supernus�s two epilepsy product candidates are SPN-538 and Epliga. Epliga is in Phase III clinical trials. Supernus ADHD product candidates include SPN-810 (molindone hydrochloride), a treatment for impulsive aggression in patients with ADHD, and SPN-812, a non-stimulant treatment for ADHD. Both of these programs are in Phase II. In addition to these four products candidates, Supernus has several additional product candidates in various stages of development, including SPN-809. Its wholly owned subsidiary includes TCD Royalty Sub LLC.